Based on these results, we reasoned that the ability of FOXM1 inhibition to target OCSC would be particularly relevant in the maintenance therapy setting, which aims at preventing or delaying OCSC-driven tumor recurrence once the bulk of the tumor has been removed by surgery and cytotoxic treatments. The gene discussed is FOXM1; the disease is neoplasm.